​
​

2seventy bio (TSVT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

2seventy bio Revenue Highlights

Latest Revenue (Y)

$100.39M

Latest Revenue (Q)

$13.53M

Main Segment (Y)

Service

2seventy bio Revenue by Period

2seventy bio Revenue by Year

DateRevenueChange
2023-12-31-9.72%
2022-12-31-67.81%
2021-12-31--78.03%
2020-12-31-460.15%
2019-12-31--18.84%
2018-12-31--

2seventy bio generated $100.39M in revenue during NA 2023, up 9.72% compared to the previous quarter, and up 183.93% compared to the same period a year ago.

2seventy bio Revenue by Quarter

DateRevenueChange
2024-09-30-50.93%
2024-06-30--27.89%
2024-03-31-16.39%
2023-12-31--11.22%
2023-09-30--66.62%
2023-06-30--13.39%
2023-03-31--25.91%
2022-12-31-318.98%
2022-09-30--0.55%
2022-06-30-59.95%
2022-03-31--47.43%
2021-12-31--16.74%
2021-09-30-162.79%
2021-06-30--38.43%
2021-03-31-20.15%
2020-12-31--46.27%
2020-09-30--83.23%
2020-06-30--
2020-03-31--

2seventy bio generated $13.53M in revenue during Q3 2024, up 50.93% compared to the previous quarter, and up 37.54% compared to the same period a year ago.

2seventy bio Revenue Breakdown

2seventy bio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Service---
Royalty And Other Revenue---
Collaboration Arrangement---

2seventy bio's latest annual revenue breakdown by segment (product or service), as of Dec 23: Service (83.87%), and Royalty And Other Revenue (16.13%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Collaboration Arrangement-----------
Service-----------
Royalty And Other Revenue-----------

2seventy bio's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration Arrangement (100.00%).

2seventy bio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SRPTSarepta Therapeutics--
ASNDAscendis Pharma--
PBYIPuma Bio--
RCUSArcus Biosciences--
TSVT2seventy bio--
PTGXProtagonist Therapeutics--
MRSNMersana Therapeutics--
RLAYRelay Therapeutics--
STOKStoke Therapeutics--
KZRKezar Life Sciences--
KDNYChinook Therapeutics--
CRNXCrinetics Pharmaceuticals--
PLRXPliant Therapeutics--
IOVAIovance Biotherapeutics--
PHATPhathom Pharmaceuticals--
CGEMCullinan Oncology--
DAWNDay One Biopharmaceuticals--
DICEDICE Therapeutics--
INZYInozyme Pharma--
REPLReplimune Group--
SNDXSyndax Pharmaceuticals--
ZNTLZentalis Pharmaceuticals--

TSVT Revenue FAQ

What is 2seventy bio’s yearly revenue?

2seventy bio's yearly revenue for 2023 was $100.39M, representing an increase of 9.72% compared to 2022. The company's yearly revenue for 2022 was $91.5M, representing an increase of 67.81% compared to 2021. TSVT's yearly revenue for 2021 was $54.52M, representing a decrease of -78.03% compared to 2020.

What is 2seventy bio’s quarterly revenue?

2seventy bio's quarterly revenue for Q3 2024 was $13.53M, a 50.93% increase from the previous quarter (Q2 2024), and a 12.46% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $8.97M, a -27.89% decrease from the previous quarter (Q1 2024), and a -75.12% decrease year-over-year (Q2 2023). TSVT's quarterly revenue for Q1 2024 was $12.44M, a 16.39% increase from the previous quarter (Q4 2023), and a -70.12% decrease year-over-year (Q1 2023).

What is 2seventy bio’s revenue growth rate?

2seventy bio's revenue growth rate for the last 3 years (2021-2023) was 84.12%, and for the last 5 years (2019-2023) was 126.63%.

What are 2seventy bio’s revenue streams?

2seventy bio's revenue streams in c 23 are Service, and Royalty And Other Revenue. Service generated $24.14M in revenue, accounting 83.87% of the company's total revenue, down -56.49% year-over-year. Royalty And Other Revenue generated $4.64M in revenue, accounting 16.13% of the company's total revenue, down -25.37% year-over-year.

What is 2seventy bio’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of 2seventy bio was Service. This segment made a revenue of $24.14M, representing 83.87% of the company's total revenue.